| Biomarker ID | 9 |
| PMID | 12171882 |
| Year | 2002 |
| Biomarker | p4036+p4749 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs Normal Prostate |
| Type of Biomarker | Diagnostic |
| Cohort | 8 Normal, 7 BPH (Benign Prostatic Hyperplasia), 9 PIN (prostatic intraepithelial neoplasia), and 7 PCA were selected from 9 patients for this study |
| Senstivity | 86% |
| Specificity | 67% |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | SELDI-TOF MS |
| Clinical | No |
| Remarks | Protein names are given as peaks identified in Mass Spectrometry; p28422 is identified as PSA (Prostate Specific Antigen) |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |